27243-15-8

Usage

Uses

Used in Chemical Synthesis:
N-SucciniMidyl 2-chloroacetate is used as a synthetic building block for the preparation of organometallic complexes and other synthetic probes. Its application in this field is due to its ability to facilitate the creation of complex molecular structures that can be used for various purposes, including the labeling of proteins.
Used in Protein Labeling:
In the field of biochemistry and molecular biology, N-SucciniMidyl 2-chloroacetate is used as a reagent for the labeling of proteins. Its reactive nature allows for the selective modification of specific amino acid residues within proteins, which can be crucial for understanding protein function, structure, and interactions.
Used in Pharmaceutical Industry:
N-SucciniMidyl 2-chloroacetate is also employed in the pharmaceutical industry as an intermediate in the synthesis of various drugs and drug candidates. Its versatility in chemical reactions makes it a valuable component in the development of new therapeutic agents.
Used in Material Science:
In the field of material science, N-SucciniMidyl 2-chloroacetate can be used as a component in the development of novel materials with specific properties. Its ability to form organometallic complexes can contribute to the creation of materials with unique electronic, magnetic, or optical characteristics.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 79-11-8 chloroacetic acid 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 1235572-58-3 C₈₄H₉₅ClN₂₀O₁₀ 
• 1613025-47-0 C₆₁H₁₀₀ClN₇O₁₈ 
• 1613025-43-6 C₄₉H₈₀ClN₇O₁₄ 
• 80028-68-8 2-<2-(2-chloroacetamido)ethyl>benzimidazole 
• 52191-26-1 2-chloro-N-<2-(indol-3-yl)ethyl>acetamide 
• 1421767-20-5 C₄₂H₄₄N₅O₁₂PS₂ 
• 67253-30-9 N-chloroacetyl-(L)-isoleucine 
• 688-12-0 N-chloroacetyl-L-leucine 
• 691-80-5 (S)-2-(2-chloroacetamido)propanoic acid 
• 1004751-66-9 C₄₅H₅₄ClN₁₁O₆ 
• 142182-09-0 1-(N-carbobenzyloxy-L-alanyl-L-alanyl-L-phenylalanyl)-2-chloroacetyl hydrazine 

Relevant academic research and scientific papers

Protein assembly directed by synthetic molecular recognition motifs

Tris-functionalized cyanuric acid (TCA) and melamine (TM) selectively recognize each other in aqueous solution with 1:1 stoichiometry. We have coupled biotin to TCA and TM to allow pseudo-tetrahedral display of TCA and TM on streptavidin through biotin-ligand binding. Synthetic cyanuric acid/melamine recognition is found to drive selective protein-protein assembly.

Design of Thioether Cyclic Peptide Scaffolds with Passive Permeability and Oral Exposure

Advances in the design of permeable peptides and in the synthesis of large arrays of macrocyclic peptides with diverse amino acids have evolved on parallel but independent tracks. Less precedent combines their respective attributes, thereby limiting the p

Synthesis and Tritium Labelling of 6β-Amino-4,5α-epoxymorphinans and Their 14-Hydroxy Derivatives as Potential Affinity Labelling Probes with μ Opioid Agonist Activity

The synthesis of 6β-(methylfumaramido) and 6β-chloroacetamido derivatives 1b and 1c of 6β-amino-7,8-didehydromorphinan and the corresponding 14-hydroxy derivatives 1e and 1f are described.The 7,8-dihydro derivatives of these compounds were synthesized in inactive (2b,c,e,f) as well as in tritiated form (3b,c,e,f).

Introduction of Peripheral Carboxylates to Decrease the Charge on Tm3+ DOTAM-Alkyl Complexes: Implications for Detection Sensitivity and in Vivo Toxicity of PARACEST MRI Contrast Agents

A series of structurally modified Tm3+ DOTAM-alkyl complexes as potential PARACEST MRI contrast agents has been synthesized with the aim to decrease the overall positive charge associated with these molecules and increase their biocompatibility. Two types of structural modification have been performed, an introduction of terminal carboxylate arms to the alkyl side chains and a conjugation of one of the alkyl side chains with aspartic acid. Detailed evaluation of the magnetic resonance imaging chemical exchange contrast associated with the structurally modified contrast agents has been performed. In contrast to the acutely toxic Tm3+ DOTAM-alkyl complexes, the structurally modified compounds were found to be tolerated well during in vivo MRI studies in mice; however, only the aspartic acid modified chelates produced an amide proton-based PARACEST signal. (Figure Presented).

Therapeutic targeting of oncogenic K-ras by a covalent catalytic site inhibitor

We report the synthesis of a GDP analogue, SML-8-73-1, and a prodrug derivative, SML-10-70-1, which are selective, direct-acting covalent inhibitors of the K-Ras G12C mutant relative to wild-type Ras. Biochemical and biophysical measurements suggest that modification of K-Ras with SML-8-73-1 renders the protein in an inactive state. These first-in-class covalent K-Ras inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling. Putting a stop to Ras: Two new selective, direct-acting covalent inhibitors of the K-Ras G12C mutant are reported. Studies suggest that the modification of K-Ras with SML-8-73-1 renders the protein inactive. These novel covalent inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling. Copyright

RAS INHIBITORS AND USES THEREOF

Described herein are compounds of Formulae (I)-(II), and pharmaceutically acceptable salts, and pharmaceutical compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases such as cancers (e.g., lung cancer, large bowel cancer, pancreas cancer, biliary tract cancer, or endometrial cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases in a subject.

Synthesis, biological evaluation, and structure-activity relationships of potent noncovalent and nonpeptidic cruzain inhibitors as anti-Trypanosoma cruzi agents

The development of cruzain inhibitors has been driven by the urgent need to develop novel and more effective drugs for the treatment of Chagas' disease. Herein, we report the lead optimization of a class of noncovalent cruzain inhibitors, starting from an inhibitor previously cocrystallized with the enzyme (Ki = 0.8 μM). With the goal of achieving a better understanding of the structure-activity relationships, we have synthesized and evaluated a series of over 40 analogues, leading to the development of a very promising competitive inhibitor (8r, IC50 = 200 nM, Ki = 82 nM). Investigation of the in vitro trypanocidal activity and preliminary cytotoxicity revealed the potential of the most potent cruzain inhibitors in guiding further medicinal chemistry efforts to develop drug candidates for Chagas' disease.

Synthesis and transport studies of model dipeptides with modified N-terminal amino groups into E. coli K12 mutant strains

The synthesis of Interminable guanidine derivatives of three dipeptides Ala-Ala, Ala-Leu, Ala-Phe and three dipeptides containing betaine as an N-terminal amino acid: Bet-Ala, Bet-Leu, Bet-He has been carried out. The transport studies of the obtained pseudopeptides and corresponding natural peptides into E. coli Kl2 mutant strains have also been performed. The results indicate that modified dipeptides containing N-terminal guanidine or betaine are not transported into E. coli K12 cells.

Analogs of Eu3+ DOTAM-Gly-Phe-OH and Tm3+ DOTAM-Gly-Lys-OH: Synthesis and magnetic properties of potential PARACEST MRI contrast agents

Chelated lanthanide ions, especially gadolinium, have found wide use as contrast agents in magnetic resonance imaging. A new paradigm for generating contrast, termed PARACEST, was recently described that requires the slow exchange of water or other exchan

Methods for the preparation of conjugated oligomers

The present invention provides novel methods for preparing oligonucleotide conjugates using a novel electrophilic haloacetyl linker. Novel compounds and intermediates are also disclosed.